Cell-mediated immune response: A clinical review of the therapeutic potential of human papillomavirus vaccination

Acta Obstetricia et Gynecologica Scandinavica

Volumn 93, Issue 12, 2014, Pages 1209-1218

  Meyer, Sonja Izquierdo ^a   Fuglsang, Katrine ^a   Blaakaer, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cellular immunity; Cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; immunity; vaccination

Indexed keywords

LEUKOCYTE ANTIGEN; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REVIEW; THERAPY EFFECT; UTERINE CERVIX CANCER; VACCINATION; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DRUG EFFECTS; FEMALE; IMMUNOLOGY; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, CELLULAR; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84912032799     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12480     Document Type: Review

References (19)

1. Schwarz TF, Leo O,. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol. 2008; 110 (3 Suppl 1): S1-10.
2. Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S,. Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis. BMC Infect Dis. 2011; 11: 235.
3. Gravitt PE,. The known unknowns of HPV natural history. J Clin Invest. 2011; 121: 4593-9.
4. Stubenrauch F, Laimins LA,. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol. 1999; 9: 379-86.
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-65.
6. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002; 8: 3676-85.
7. Singer A, Jordan JA, Stanley MA,. HPV and the Vaccines: Myths and Misconceptions. Immunological Answers to Key Questions. London: S W Health Ltd., 2009.
8. Bellone S, Pecorelli S, Cannon MJ, Santin AD,. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 2007; 7: 1473-86.
9. Thappa DM, Nath AK,. Vaccines for human papillomavirus infection: a critical analysis. Indian J Dermatol Venereol Leprol. 2009; 75: 245-54.
10. Ma B, Xu Y, Hung C, Wu T,. HPV and therapeutic vaccines: where are we in 2010? Curr Cancer Ther Rev. 2010; 6: 81-103.
11. Roden RB, Ling M, Wu TC,. Vaccination to prevent and treat cervical cancer. Hum Pathol. 2004; 35: 971-82.
12. Michel N, Ohlschlager P, Osen W, Freyschmidt EJ, Guthohrlein H, Kaufmann AM, et al. T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining. Intervirology. 2002; 45: 290-9.
13. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Vaccination: intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014; 6: 221ra13.
14. Lee YS, Lee CW, Song MJ, Ho EM, Kim CJ, Park TC, et al. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia. Acta Obstet Gynecol Scand. 2011; 90: 1350-6.
15. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009; 15: 361-7.
16. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer. 2007; 121: 2794-800.
17. Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2004; 53: 642-50.
18. Frazer IH, Leggatt GR, Mattarollo SR,. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol. 2011; 29: 111-38.
19. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-8.